Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
28.12
+0.51 (1.85%)
Apr 29, 2026, 1:25 PM CST
141.17%
Market Cap 13.19B
Revenue (ttm) 203.92M
Net Income (ttm) -83.86M
Shares Out 477.77M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,111,981
Average Volume 54,522,916
Open 28.41
Previous Close 27.61
Day's Range 26.51 - 28.41
52-Week Range 9.90 - 66.66
Beta 0.78
RSI 44.37
Earnings Date Apr 28, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 484
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2025, SHE:300204's revenue was 220.23 million, a decrease of -32.20% compared to the previous year's 324.82 million. Losses were -77.76 million, -46.31% less than in 2024.

Financial Statements

News

There is no news available yet.